Business
CStone Announces Clinical Progress Update on CS2009
CStone Announces Clinical Progress Update on
About this update from Cstone Pharmaceuticals
[{"type":"text","content":"Suzhou, China - CStone Pharmaceuticals ('CStone', HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced that clinical progress update on CS2009, a potential first-in-class/best-in-class PD-1/VEGF/CTLA-4 trispecific antibody independently developed by CStone.\nIt features balanced and monovalent PD-1 and CTLA-4 arms and a bivalent anti-VEGFA arm, which leads to potent multi-target synergy and preferential targeting of tumor tissue to reduce systemic toxicity.\nCS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells via avidity-driven engagement, while minimizing interference with CTLA-4 signaling in peripheral T cells, thus potentially offering enhanced efficacy with lower systemic toxicity. In the tumor micro-environment (TME), CS2009's anti-PD-1 and anti-CTLA-4 activities are further enhanced significantly by crosslinking with VEGFA dimers that are upregulated in the TME.\nKey Highlights\nThe global multicenter Phase I/II study is actively enrolling patients in Australia and China, with planned expansion to the United States for Phase II enrollment. With strong interests from investigators and patients, the trial is enrolling speedily and expected to exceed 100 patients by the end of this year.\nThe Phase Ia dose escalation study has evaluated four dose levels in patients with advanced and heavily pretreated solid tumors. Dose level 4 at 20 mg/kg, Q3W has just passed safety evaluation by the Safety Monitoring Committee (SMC) without identifying any Dose Limiting Toxicity (DLT). The study is currently enrolling at Dose Level 5 (30 mg/kg, Q3W) to establish a wide safety margin over potential recommended phase 2 dose (RP2D), while backfilling is ongoing for prior dose levels (1-20 mg/kg, Q3W). Phase Ib/II dose expansion/pivotal extension studies are anticipated to commence in the second half of 2025.\nTo date, CS2009 is found to be well tolerated across all evaluated dose levels, with excellent pharmacokinetic (PK) profile supporting Q3W dosing, with pharmacodynamic (PD) responses indicating both T cell activation from PD-1 and CTLA-4 blockade and VEGFA neutralization. Anti-tumor activities have been observed from lower-dose cohorts in patients with 'cold' tumors and PD-(L)1 pretreated tumors.\nPhase Ia data (including safety, PK, PD, and antitumo...